Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

‘Imminent’ Generic Approvals Expected To Help US FDA Meet On-Time Review Metric Retroactively

Executive Summary

ANDA action rate dipped below the 90% mandate in second fiscal quarter, another illustration of the effect the pandemic and other issues have on US FDA’s generic drug assessment system.

You may also be interested in...



Congress Already Preparing For User Fee Bills

Multiple congressional offices attended a briefing on GDUFA III with FDA and industry officials, suggesting plans for the must-pass bill already are in the works.

FDA Avoided Half Of ANDA Pre-Approval Inspections During COVID By Using Alternative Tools

Records reviews are common now in lieu of an in-person inspection for US generic applications, but more virtual facility checks could be coming soon.

Bad Miss For Biocon’s Bevacizumab In US But Firm In 'Good Place'

Biocon awaits site inspection after pandemic-amplified delays keep its Viatris-partnered bevacizumab out of the US market, though the Indian company believes they can still make good and garner market share. All eyes are also on traction for their insulin glargine via increased share of formulary contracts.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS144264

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel